Table III.
Frequency of adverse events and laboratory abnormalities.
| TFTH + BV, n=17 (%) | ||
|---|---|---|
| Adverse events | All grade, n (%) | Grade 3/4, n (%) |
| Hematological | ||
| Neutropenia | 11 (64) | 7 (41) |
| Leukopenia | 11 (64) | 1 (11) |
| Anemia | 8 (47) | 1 (5) |
| Non-hematological | ||
| Increased blood bilirubin | 7 (41) | 1 (5) |
| Increased ALT | 7 (41) | 1 (5) |
| Increased AST | 6 (35) | 1 (5) |
| Increased ALP | 6 (35) | 1 (5) |
| Febrile neutropenia | 0 (0) | 0 (0) |
| Hypertension | 5 (29) | 1 (5) |
| Anorexia | 7 (41) | 0 (0) |
| Oral mucositis | 2 (11) | 0 (0) |
| Proteinuria | 9 (52) | 0 (0) |
| Nausea | 8 (47) | 0 (0) |
| Diarrhea | 8 (47) | 0 (0) |
| Vomiting | 2 (11) | 1 (5) |
| Fatigue | 10 (58) | 0 (0) |
| Fever | 2 (11) | 1 (5) |
| Skin rash | 6 (35) | 0 (0) |
| Epistaxis | 5 (29) | 0 (0) |
TFTD, trifluridine and tipiracil hydrochloride; BV, bevacizumab; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase.